All News

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Check out important updates from the FDA for the week of April 22.

Continuous glucose monitors (CGMs) empower patients with diabetes to take a more active role in managing their condition, but without proper training, many of these advantages become limited.

Fidanacogene elaparvovec-dzkt (Beqvez) is a 1 time treatment that allows patients with hemophilia B to produce factor IX themselves.

US health officials are growing increasingly worried about rising syphilis cases and have begun creating framework to slow down the spread.

The clinical manifestations of shingles can be divided into 3 phases.

Check out these featured Drug Topics expert interviews from April 2024.

A Q&A with Kirollos Hanna, PharmD, director of pharmacy at Minnesota Oncology, on the current and future landscape of bispecific antibodies in myeloma treatment.

Amneal Pharmaceuticals said its generic naloxone hydrochloride nasal spray is now available in the US following FDA approval.

Despite a wealth of knowledge, pharmacists are frequently not consulted as part of the decision-making team in atrial fibrillation management.

A new study found that cloud-based CGM monitoring services provided statistically significant improvements in high time above range, time in range, and average glucose.

With expertise through antimicrobial stewardship experience, researchers believe antimicrobial stewardship pharmacists are vital in assisting diagnostic stewardship.

A Q&A with Douglas Hoey, CEO of NCPA, on ways to change the pharmacy payment model and deceptive practices being employed by PBMs.

Check out these top featured stories from Drug Topics in April 2024.

By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

Collecting smell and taste scores from individuals with and without a history of COVID-19, researchers found significantly lower scores for smell in COVID-19-diagnosed individuals.

Abeona Therapeutics’ pz-cel is an investigational autologous, COL7A1 gene-corrected epidermal sheet therapy for the treatment of recessive dystrophic epidermolysis bullosa.

The action taken by CVS staffers seems to be the only way to get the attention of corporate officials.

A higher patient-rated therapeutic alliance was associated with improvements in depression outcomes up to 1 year after treatment.

According to Scott Soefje, PharmD, understanding nuances across sites of care can help health care providers optimize patient care delivery while ensuring financial viability across all settings.

Karen Fancher, PharmD, addresses how hearing the perspectives of colleagues can offer invaluable support to shape individualized approaches to ethical dilemmas in oncology pharmacy.

In case you missed it, this week we had news about potential pharmacy unions, states' regulation of PBMs, rising insulin costs, and more.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Check out important updates from the FDA for the week of April 15.

While prioritizing either cost or margin may be necessary at a site of care, big picture items, such as societal responsibility and long-term health care affordability, should guide financial analyses, said Scott Soefje, PharmD.

Representatives from the US Government Accountability Office (GAO) interviewed regulators from 5 states on pharmacy benefit manager laws.

Listening carefully to determine what’s beneath the surface of a patient’s concerns can make a world of difference in providing quality care.

This approval is the second biosimilar approval for manufacturer Alvotech.

Digital therapeutics are positioned as front-runners in the increasingly digital future of health care.